T-cell Lymphoma Clinical Trial
Official title:
A Sing-Arm, Open Clinical Pharmacology Study of Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in patients with Relapsed or Refractory T-cell Lymphoma. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01.
Status | Not yet recruiting |
Enrollment | 6 |
Est. completion date | December 2023 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female aged = 18 years. 2. The following of typesRelapsed T-cell lymphoma (TCL): peripheral T-cell lymphoma (PTCL) [peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell (ALCL)], and cutaneous TCL (CTCL) of mycosis fungoides (MF). 3. Patients have received at least 1-line systemic treatment in the past and who have relapsed or are refractory: failed to achieve complete remission (CR) or disease progression (PD) after CR, ineligible for autologous hematopoietic stem cell transplantation (ASCT) or PD after ASCT. 4. There is at least one measurable lesion without previous local treatment, which the long axis of the intranodal lesion is >15 mm or extranodal lesion >10 mm According to Lugano 2014 criteria. 5. Patients Eastern Cooperative Oncology Group (ECOG) physical status score must be 0 or 1. 6. Life expectancy=3 months et al. Exclusion Criteria: 1. Subjects with brain metastasis and/or clinically history tumor brain of metastasis; 2. Subjects who have received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc within 2 weeks before RT-01 administration; 3. Subjects who have participate in another interventional study within 4 weeks before RT-01 administration; 4. Subjects who have had major surgery within 4 weeks before RT-01 administration. 5. Patients in any condition requiring systemic treatment with corticosteroids (prednisone > 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days before RT-01 administration, but currently or previously treated with any of the following steroid regimens, were included: Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; Prophylactic short-term use of corticosteroids; 6. Subjects who have participate in another oncolytic virus study within 8 weeks before RT-01 administration; 7. Subjects received live vaccines within 7 days before RT-01 administration; 8. Subjects received Antiviral drugs within 2 weeks, long-acting interferon within 4 weeks before RT-01 administration# 9.Subjects with adverse reactions caused by previous anti-tumor treatment not recovered to (CTCAE 5.0) grade 1 (except alopecia); 10.Subjects who have uncontrolled active infection; 11.Subjects with known positive history of human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS); 12.Subjects who have active hepatitis; 13.Subjects who have serious cardiovascular system disorders history; 14.Clinically uncontrollable third space effusion,are considered unsuitable for this study in the opinion of the investigator; 15.Subjects with active autoimmune diseases or history of autoimmune diseases that may relapse; et al. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital Bengbu Medical College |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events | Graded according to the NCI CTCAE version 5.0. | Up to 6 months | |
Primary | To evaluate objective Response Rate (ORR) of the antitumor activity | To assessed per Lugano and Lyric | Up to 2 years | |
Primary | To evaluate the disease control rate (DCR) of the antitumor activity | To assessed per Lugano and Lyric | Up to 2 years | |
Primary | The changes of the immunoreactivity during treatment | Peripheral blood T lymphocyte subtype | Up to 28 days | |
Primary | To evaluate the immunogenicity of RT-01 | Antiviral antibody | Up to 28 days | |
Primary | To evaluate the viral shedding of RT-01 | Viral RNA | 8 weeks after last dose | |
Primary | The Cmax of Viral RNA | The maximum RNA peak concentration | 8 weeks after last dose | |
Primary | The Tmax of Viral RNA | The time of maximum RNA peak concentration | 8 weeks after last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00959686 -
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT04712864 -
Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05665530 -
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies
|
Phase 1 | |
Completed |
NCT01941680 -
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
|
||
Recruiting |
NCT05075460 -
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
|
Phase 3 | |
Completed |
NCT03734601 -
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
|
Phase 2 | |
Completed |
NCT02017613 -
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
|
Phase 1 | |
Enrolling by invitation |
NCT01854112 -
Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma
|
N/A | |
Completed |
NCT01553786 -
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
|
Phase 2 | |
Completed |
NCT00542919 -
A Study for Patients With Non-Hodgkin's Lymphomas
|
Phase 2 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Active, not recruiting |
NCT03952078 -
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
|
Phase 1 | |
Completed |
NCT02424045 -
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma
|
Phase 2 | |
Completed |
NCT01871675 -
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
|
Phase 1 | |
Terminated |
NCT00893516 -
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
|
Phase 2 | |
Completed |
NCT01902225 -
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT02086591 -
A Phase II Study of Doxycycline in Relapsed NHL
|
Phase 2 | |
Recruiting |
NCT04264078 -
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
|
Early Phase 1 | |
Completed |
NCT00001582 -
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
|
||
Completed |
NCT00322985 -
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
|
Phase 2 |